Biopharmaceuticals and gene therapy: Redefining modern medicine

Abstract

Biopharmaceuticals, medicinal products derived from living organisms through advanced biotechnological methods, encompass recombinant proteins, monoclonal antibodies, vaccines, and nucleic acid-based therapies. Gene therapy, a transformative subset of biopharmaceuticals, involves the introduction of genetic material into cells to correct faulty or deficient genes, aiming to treat or prevent disease at its molecular origin. From January 2018 to June 2022, 196 new biopharmaceuticals were approved in the U.S. and/or EU, with monoclonal antibodies dominating the landscape. As of early 2025, the FDA has approved over 30 cell and gene therapies, and industry experts anticipate 30–50 additional approvals by 2030. Gene therapy approaches including gene addition, gene silencing, and genome editing employ viral vectors (AAVs, lentiviruses) and non-viral delivery systems. Clinical applications span genetic disorders, cancers, and infectious diseases, with CAR T-cell therapies and mRNA vaccines marking significant milestones. Despite this progress, high costs, immune responses, and long-term efficacy remain significant barriers. Future directions include AI-driven drug discovery, advanced delivery systems, and expanded manufacturing capabilities. Biopharmaceuticals and gene therapies are poised to redefine modern medicine by offering precise, personalized, and potentially curative treatments.